Hanall Biopharma Co., Ltd. (KRX:009420)

Hanall Biopharma Revenue

Hanall Biopharma had revenue of 40.03B KRW in the quarter ending March 31, 2026, with 10.73% growth. This brings the company's revenue in the last twelve months to 159.06B, up 12.81% year-over-year. In the year 2025, Hanall Biopharma had annual revenue of 155.18B with 11.69% growth.

• Revenue (ttm): 159.06B
• Revenue Growth: +12.81%
• P/S Ratio: 18.48
• Revenue / Employee: 523.24M
• Employees: 304
• Market Cap: 2.94T

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	155.18B	16.24B	11.69%
Dec 31, 2024	138.94B	4.03B	2.99%
Dec 31, 2023	134.91B	24.91B	22.65%
Dec 31, 2022	110.00B	8.40B	8.27%
Dec 31, 2021	101.59B	12.99B	14.66%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 4, 2026

Data Sources Report a data error